Member Info for moonparty

ftse, "Sadly, imo, 8p before 30p" - c'mon, that is painfully transparent.

*hasiba, *Avidimab, scuse my fat fingers

haisba,
"So from now until the H1 ....what are they going to do" - well, advance the products and trials, like he said. And all the other BAU activites - Lindy doing her thing (the new pre-cancer vaccine discussed earlier?), ongoing collaborations and research.
I don't think it was a terrible interview, just not pandering to the short-termism of AIM traders. No surprises - we kind of new no trials were going to start Q1 with lockdown. Shame there wasn't time to talk about Aidmab and Biontech/Carolina collaborations.

Great discussion today, really enjoyed reading all the posts.
It's made me re-realise what an amazing potential Scancell have, and how close we are to lift off.
Possible RNS Monday morning then re. Covidity progress :)

And though of a few more
- additional government funding for covidity
- publishing of scientific papers
- news on patents
- director buying
- institutional buying

It's extremely unlikely we are about to enter any kind of news vacuum!

Sorry, have to disagree with this:
"then it is unlikely that there will be any significant news coming in the near term, nor will there be any significant price moves"
Significant news that could come at any time:
- news on lab work and progression to trial on covidity
- start of trials
- trial recruitment,
- avidimab progress
- avidimab deals
- new products (Lindy has form on this!)
- left field (Scancell has form)

Any of these could could come at any time, and there's a really high chance of at least one of these in the next month, possibly several.
Any of these would have a significant impact on the sp.

Thanks researcher, that's reassuring :)

A little concerned by this in the RNS:
"Parsortix was comparable to the leading antibody-based system with respect to time required for sample processing, staining and cell identification and was considerably faster than some other systems".

Does anybody have any knowledge of the "leading antibody-based system" and how that compares to Parsortix in terms of cost.?

Also, "considerably faster than some other systems" is a little vague, I would like to have more exact information than this.

I will try and find time to look at the full report later.

Nor was I. Balerno1, can you tell us where your information come from? Thanks.
"Yes we have an unnamed partner but why no further published progress? "

If approval is not given the sp will tank, short term, though this seems pretty unlikely.
Longer term, you can reapply - the FDA would provide feedback and adjustments could be made before re-applying.
AGL have put in a lot of effort to ensure approval first time round. To me at least that's the odds-on favourite outcome.

I'm fully out as of this morning. Watch Togo licence get announced later today, lol.
Only been in since October 2019, so got (and still hold) Calidus, and have made a decent return on the combined shares.
It's a shame as I rate the directors and still think KRS will do well, but the Togo situation is untenable, to me at least. And every dilution reduces the potential return of Togo being finalised.
Will keep a close eye and may jump back if/when there is Togo news. Good luck to al holders.

A trade of 66,666 shares - gotta be a sign. Keras have signed a deal with the devil ?? :)

C'mon guys, this isn't the time or plaice

10,000,000 shared trade at 0.1101
That's got to be a secret market maker code :)
Is it binary for 'fill your boots' :)

That's disengenious at best RR, both their most recent direct investments were at 13p.
Yes they have invested at cheaper prices also, but their most recent investment is really what matters, as it is the most recent valuation of the company.

45p more likely today :)
Looks like big sellers are out now - steady buying is leading to the price going up. All is back to normal. I hope.

researcher1, so what you are saying is "bet your house on it" :)

I agree, for what it's worth.

to reiterate the point that it is only Jupiter selling, for reasons that are available in the public domain, and not a reflection on Angle.
Other institutions / funds / wealthy PIs bought £20M in the recent placing at 46p, far more than Jupiter have sold.

Also, I think Jupiter might be finished now - I couldn't buy 25K earlier without going to the full 43p offer - indicates to me the 'guaranteed seller', aka Jupiter, is no longer present ?

After FDA there will be a scramble to buy Angle IMO. Anyone have any figures for potential market size / revenue etc.., then we might be able to have a stab at a takeover price?

Dibs, Jupiter are offloading shares into the market at the moment, which explains the current sp - they shouldn't have too many left now. Not a refelction on AGL btw, Jupiter are in trouble and need cash.